A convenient synthetic protocol for the unprecedented N-hydroxylation of proline residue in Melanostatin (MIF-1) neuropeptide is reported. This methodology is grounded on the incorporation of N-(cyanoethyl)prolyl residue followed by on-site oxidation by Cope elimination with m-chloroperbenzoic acid, exploring the unrecognized dual role of the cyanoethyl group as an effective N-protecting group under peptide synthesis conditions and as a suitable leaving group during the chemoselective on-site N-oxidation. Following this protocol N-hydroxy-MIF-1 is obtained in 78% global yield from N-(cyanoethyl)-l-proline. This synthetic approach opens a new avenue for access to N-hydroxylated Melanostatin analogues with direct application in neurochemistry and Parkinson’s research.
4 November 2024 in ACS Sustainable Chemistry & Engineering
Melanostatin (MIF-1) is an endogenous tripeptide that acts as a positive allosteric modulator (PAM) of the dopamine D2 receptors (D2R), making it a valuable pharmacological lead for the treatment of dopamine-related disorders of the central nervous system (CNS). In this study, a novel series of MIF-1 derivatives was synthesized and pharmacologically evaluated to investigate the influence of ring flexibility and stereochemistry on PAM activity. For this purpose, the alicyclic β-amino acids (1R,2S)-2-aminocyclopentane-1-carboxylic acid (cispentacin) and its unsaturated precursor, (1R,2S)-2-aminocyclopent-3-ene-1-carboxylic acid, were used as proline surrogates. The results obtained showed that cispentacin-based derivatives 8b and 9b displayed PAM activity at 10 pM, significantly reducing the EC50 of dopamine by 4.34- and 4.22-fold, respectively (8b: EC50 = 20.08 ± 3.95 nM; 9b: EC50 = 20.61 ± 4.60 nM). At 1 nM, 8b further decreased the EC50 of dopamine by 9.20-fold (EC50 = 9.47 ± 5.02 nM) and, at higher concentrations (10 and 100 μM), it activated the D2R in the absence of dopamine, representing the first-in-class MIF-1-based ago-allosteric modulator of the D2R. Cytotoxicity assays in human dopaminergic-differentiated SH-SY5Y cells showed that neither 8b nor 9b exhibited cytotoxic effects at 100 μM, as assessed by both the MTT reduction and neutral red uptake assays, supporting their favorable toxicological profiles. Overall, these findings demonstrate that a fine-tuned interplay between ring flexibility and stereochemistry is a key determinant in generating effective PAM of the D2R, providing a framework for the future design of MIF-1-based modulators targeting Parkinson's disease and other dopamine-related CNS disorders.
Melanostatin (MIF-1) is an endogenous positive allosteric modulator (PAM) of dopamine D2 receptors (D2R) with recognized therapeutic potential in central nervous system (CNS) disorders associated with dopaminergic dysfunction, particularly Parkinson's disease. However, the therapeutic development of MIF-1 has been limited by poor pharmacokinetic properties. Building on previous studies of conformationally constrained MIF-1 analogs, the present work describes the design, synthesis, and comprehensive functional, toxicological, and permeability evaluation of new bridged derivatives incorporating the enantiopure scaffold (1R,3S,4S)-2-azanorbornane-3-carboxylic acid as a hybrid prolyl/pipecolyl surrogate. The target MIF-1 derivatives were synthesized through a concise and stereoselective route, and their absolute configuration was unequivocally established by X-ray crystallography. Pharmacological assays at human D2R identified four active derivatives (7b, 8d, 9c, and 9d) that potentiated dopamine responses by 5.3- to 6.6-fold at concentrations as low as 10 pM, consistent with PAM-like activity. Toxicological profiling in HepG2 (100 µM) and differentiated SH-SY5Y neuronal cells (up to 200 µM) confirmed that these compounds are well tolerated at supra-pharmacological concentrations, except for 9c. Additionally, these compounds exhibited reduced P-gp-mediated efflux and improved Caco-2 permeability compared to MIF-1. Overall, these findings identify 2-azanorbornane as a promising scaffold for the development of D2R PAM ligands with favorable pharmacokinetic and safety profiles.